How long does Wegovy take to start working?
Initial loss within 4-6 weeks; titration to 2.4 mg over 16-20 weeks.
What is the maintenance dose?
2.4 mg weekly; sometimes 1.7 mg for patients who can't tolerate 2.4 mg.
Should my dose be higher than 2.4 mg?
No; 2.4 mg is the maximum approved dose.
Why did I lose quickly then stop?
The biological plateau pattern; metabolic adaptation defends new weight.
Do I need to track calories?
Not necessarily; can be useful for diagnosing compensation patterns.
Can stress prevent weight loss?
Yes; chronic stress elevates cortisol and drives emotional eating.
What if I'm losing inches but not pounds?
Body composition change; muscle gain and fat loss can mask scale change.
Should I switch to tirzepatide?
Discuss with prescriber; tirzepatide produces higher mean weight loss in trials.
Can long-term Wegovy use stop working?
Tolerance is not well-documented; continued use typically maintains loss.
Related guides
- Why Am I Not Losing Weight on Ozempic? The Six Causes Worth Investigating
- Why Am I Not Losing Weight on Mounjaro? Plateau Patterns and Real Causes
- Why Am I Not Losing Weight on Zepbound? Plateau Realities and Course Correction
- Why Am I Not Losing Weight on Semaglutide? Brand and Compounded Considerations
- Why Am I Not Losing Weight on Tirzepatide? Decoding Stalled Progress
- Not Losing Weight on Ozempic: A Troubleshooting Checklist
Sources
- Wilding JPH et al., "Once-Weekly Semaglutide in Adults with Overweight or Obesity," NEJM, March 2021 (STEP 1)
- Rubino D et al., "Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance," JAMA, April 2021 (STEP 4)
- Lincoff AM et al., "Semaglutide and Cardiovascular Outcomes," NEJM, November 2023 (SELECT)
- Wegovy FDA prescribing information
- Jastreboff AM et al., SURMOUNT-1, NEJM 2022
- Tasali E et al., JAMA Internal Medicine, March 2022
- Endocrine Society Clinical Practice Guideline on Obesity, 2023
- American Thyroid Association screening guidelines
- NAMS position statements on weight in menopause
- CDC alcohol use guidelines
- National Sleep Foundation duration recommendations
- ACSM exercise guidelines for adults with overweight
Footer disclaimers
Platform Disclaimer. FormBlends connects patients with licensed clinicians. This article is educational and does not replace individual clinical assessment. Discuss specific situations with your prescriber.
Get medications from a trusted source
FormBlends sources through 503A compounding pharmacies with third-party purity testing on every batch.
Start Free Assessment →Compounded Medication Notice. Compounded semaglutide is prepared by 503A pharmacy partners for individual patients with documented clinical justification. Not FDA-approved. STEP trial data applies to brand Wegovy specifically.
Results Disclaimer. Individual outcomes vary. STEP 1 reported a 14.9% mean weight loss at week 68 with semaglutide 2.4 mg; the distribution included high responders and modest responders. Your result depends on dose, adherence, baseline weight, lifestyle, and physiology.
Trademark Notice. Wegovy, Ozempic, and NovoCare are trademarks or service marks of Novo Nordisk A/S. FormBlends is independent.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →